clinical trial · NCT07502014
A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer
Huazhong University of Science and Technology·phase2·not yet recruiting·n = 60
Metastatic Colorectal Cancer (CRC)mCRCIparomlimab and Tuvonralimab (QL1706)FruquintinibHeterogeneous Radiotherapy
brief summary
This is a randomized, parallel, open-label, multicenter exploratory clinical study designed to investigate the efficacy and safety of iparomlimab and tuvonralimab in combination with fruquintinib plus heterogeneous radiotherapy, compared with fruquintinib monotherapy, as the third-line and subsequent-line treatment for patients with oligometastatic colorectal cancer.
started
May 1, 2026
primary completion
Dec 31, 2028
completion
Dec 31, 2029
last updated
Mar 30, 2026
official title
A Randomized, Parallel, Open-Label, Multicenter Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol